Robin Verjans completed his Bachelor Health Sciences, with major Bioregulation and minor Movement Sciences, at Maastricht University in 2011. During his Bachelor he performed an internship at the department of Human Biology under the supervision of Prof. Ronald Mensink and Prof. Jogchum Plat. During this 6-month during internship he focussed on the influence of the C/EBPβ isoforms LIP and LAP on ApoA-1 production in HepG2 cells. As an element of this internship he wrote a literature review: HDL Functionality as Protective Factor for Future Cardiac Diseases.
Robin obtained his M.Sc. degree in Biomedical Sciences at the University of Maastricht in 2013, with the specialisation Cardiovascular Biology and Medicine. During his Master, he performed his junior internship at the department of Pathology in Academic Hospital Maastricht (AZM) under the supervision of assistant professor Judith Sluimer. The title of his internship was: Reoxygenating carbogen treatment decreases hypoxia in murine atherosclerotic plaques and increases aterial pO2 and efferocytosis efficiency. From this work he obtained a co-authorship publication (Marsch et al., 2014). Robin joined the group during his senior master internship where he studied the role and underlying mechanism of miR-139 and miR-582 in cardiac hypertrophy under the supervision of Blanche Schroen. Robin started his work as a PhD student for the group of Prof. Stephane Heymans after his internship and obtaining his masters degree.
His interest in cardiovascular biology and research has brought him to join the group Prof. Stephane Heymans. During his PhD, he will perform a high-throughput phenotypical screen at Cenix BioSciences (Dresden, Germany) to identify miRNAs involved in heart failure-underlying processes, such as cardiac hypertrophy, fibrosis and inflammation. In addition, he will focus on the role of different miRNAs in cardiac (patho)physiological hypertrophy and unravelling the underlying mechanisms.